Enanta Pharmaceuticals | ENTA - Чистый доход





Чистый доход Изменить Дата
AbbVie USD 1.82B 1.63B 2025-12
Amgen USD 1.33B 1.88B 2025-12
Anika Therapeutics USD 292K 2.62M 2025-12
Arrowhead Research USD 30.81M 54.56M 2025-12
AstraZeneca USD 2.33B 207M 2025-12
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Biogen USD 466.5M 168.3M 2025-09
Bristol-Myers Squibb USD 1.09B 1.11B 2025-12
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Gilead Sciences USD 2.18B 869M 2025-12
GlaxoSmithKline GBP 636M 1.38B 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Immunic USD -24.37M 2.99M 2024-09
Incyte USD 299.28M 124.89M 2025-12
Insmed USD -328.48M 41.54M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
J&J USD 5.12B 36M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Ligand Pharmaceuticals USD 117.27M 112.43M 2025-09
Merck USD 2.96B 2.82B 2025-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novartis USD 2.41B 1.52B 2025-12
Novavax USD 17.53M 219.91M 2025-12
Pfizer USD -1.65B 5.19B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12